Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05253911 2025-12-04

TRACE

Completed

49 enrolled

Breast

HER2-positive Breast Cancer

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast

Breast Neoplasms

NCT04220203 2025-06-26

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Approved for marketing

Breast

HER2-positive Breast Cancer

Clinical Trials

BREnnA

HER2CLIMB-05

MOUNTAINEER-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

HER2CLIMB-04

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

MK-1022-009

MK-7119-001

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

DB-07

TRACE

PIKture-01

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer